Dec 23, 2024 · In 2024, several significant advancements in breast oncology were covered by Targeted Oncology TM. Here are the top 10 developments from the year: FDA Approval of Inavolisib for Advanced Breast Cancer: The FDA approved inavolisib (Itovebi, previously GDC-0077) plus palbociclib (Ibrance) and fulvestrant for the treatment of hormone receptor–positive (HR+), HER2-negative (HER2-), PIK3CA ...

Nov 13, 2024 · Targeted Oncology: Do you consider this patient with metastatic breast cancer (mBC) to be eligible for sacituzumab govitecan (Trodelvy)? Aditya Bardia, MD, MPH , FASCO: If you look at the label of sacituzumab govitecan, it says 2 prior lines of systemic therapy; it does not say which kind, so you can make a case that the endocrine-based treatment was also systemic therapy. 1 But the TROPiCS-02 ...

Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.

Dec 23, 2024 · Dual immune checkpoint inhibition with nivolumab (Opdivo) and ipilimumab (Yervoy) shows promise for the treatment of anaplastic thyroid cancer (ATC), but offers limited benefit for those with radioiodine refractory differentiated thyroid carcinoma (RAIR DTC), according to findings from a phase 2 study (NCT03246958). 1 The study sought to evaluate the efficacy of these immunotherapies in ...

Nov 12, 2024 · In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.

Nov 14, 2024 · The treatment options for follicular lymphoma (FL) are rapidly advancing, driven by the development of new, promising therapies. At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory FL.

Dec 11, 2024 · Aditya Bardia, MD, MPH, FASCO, professor, department of medicine, division of hematology/oncology, director of translational research integration, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, discusses how fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) compares with physician’s choice of chemotherapy in estrogen receptor (ER)-positive/HER2-low breast cancer and how ...

Dec 12, 2024 · A statistically significant and clinically meaningful median progression-free survival (PFS) improvement was demonstrated with palbociclib (Ibrance) plus standard-of-care therapy in patients with hormone receptor–positive, HER2-positive metastatic breast cancer as first-line maintenance therapy. 1 “Our results really reinforce the …

Dec 20, 2024 · Solly Chedid, MD, discussed luspatercept and its role in boosting quality of life for patients with myelodysplastic syndrome.

Dec 3, 2024 · Saad Z. Usmani, MD, MBA, FACP, FASCO, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, discusses the results and potential impact from the phase 3 CEPHEUS trial (NCT03652064) of daratumumab and hyaluronidase-fihj (subcutaneous daratumumab; Darzalex Faspro) with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of patients with newly diagnosed multiple ...